Going Beyond to Advance Treatments for Patients with Acid-related Disorders

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.

Syndicate Partners
  • Abingworth, LLP
  • Frazier Healthcare
  • RA Capital Management
  • Medicxi
  • Blackwell Partners
  • Janus Henderson
  • Biotechnology Value Fund
  • Richard King Mellon
  • Greenspring
  • Marshfield Advisers
  • Sahsen Ventures

Three Questions Answered

Dr. Tachi Yamada
Dr. Tachi Yamada
Chairman and Co-founder of Phathom Pharmaceuticals
What is the unmet medical need addressed by your clinical drug candidate vonoprazan?

Patients with erosive esophagitis fail to respond to existing treatments with proton pump inhibitors in almost a third of cases. Vonoprazan promises to provide adequate treatment of these patients. In addition current regimens for eradicating H. pylori infection have diminished in efficacy with the standard proton pump inhibitors. Antibiotic regimens used in combination with Vonoprazan have been shown to be effective in eradicating infection in more than 90% of patients.

What is the significance of trying to develop an asset through a new company like Phathom?

Phathom combines the talents of an experienced team of clinical development experts with those of experts in new company creation backed by a strong syndicate of investors. New companies so constituted have proved to be highly efficient and resourceful in developing new medicines to bring them to patients quickly and with minimum of expense.

Do you think Japan can benefit further by developing assets through newly created venture-backed companies like Phathom?

Japan has proved to be a fertile environment for the discovery of new medicines because of its strong science base and deep knowledge of Pharmaceutical development. To date Japan has not been less successful in translating these qualities into evolution of a vibrant venture-backed biotech sector. Phathom and one of it’s investors, Catalys Pacific, provides one opportunity which we hope will help to bring about change in this situation. It also illustrates how global large pharmaceutical companies are increasingly partnering their assets with start-up companies like Phathom to develop some of their assets taking advantage of alternative sources of funding as well as the productivity of a focused experienced team unfettered by the usual impediments encountered in large companies.